Characterize the Links Between Sleep, Emotional Dysregulation and Learning in Neurodevelopmental Disorders.

Prior treatment

• Transmeridian travel (\> 2 time zones) in the month prior to study inclusion
• Modification of psychotropic medication in the 2 months prior to inclusion
• Use of melatonin-based dietary supplement(s)/medication(s) in the 24 hours prior to study inclusion
• Participation in research involving an experimental drug which may interfere with the protocol\*.
• Subject in a period of exclusion (determined by a previous or current study)

Other illness

• \- Current or past neurological problem(s) (e.g. stroke, epilepsy, meningitis, head trauma with loss of consciousness of more than 15 min, concussion, brain tumor, ...).
• Presence of a mood disorder (bipolar disorder or depression) according to DSM-5 criteria
• Cognitive-behavioral therapies (CBT) targeting sleep disorders

Other

• tumor, ...)
• Social jet-lag \> 2 hours (mid-point of sleep differential during weekends vs. weekdays)
• Use of psychostimulant(s) within 48 hours of study entry
• Extreme chronotype (Morningness/Eveningness questionnaire score \< 10 or \> 42)
• Minor under guardianship
• Subject in emergency situation

• Subjects aged 7 to 12
• Able to receive clear, age-appropriate information and to participate fully in the study
• Whose legal representative(s) are able to understand the objectives and risks of the research and to give their dated and signed informed consent.
• Subjects benefiting from a social health insurance plan (beneficiary of the legal representative(s))
• With a diagnosis made prior to inclusion of Autism Spectrum Disorder (ASD) or Attention Deficit Disorder with or without Hyperactivity (ADHD) as defined by Diagnostic and Statistical Manual 5 (DSM-5).
• With abbreviated intelligence quotient \> 80 measured by Wechsler Intelligence Scale for Children version IV (WISC-IV )no more than 6 months prior to research inclusion
• No diagnosis of: fragile X syndrome, Rett syndrome, trisomy 21, tuberous sclerosis of Bourneville, von Recklinghausen disease, Cytomegalovirus encephalitis (CMV encephalitis), congenital rubella, phenylketonuria
• No clinically significant abnormality which, in the investigator's opinion, could interfere with the implementation of the study.